Glucokinase activators contribute to gastrointestinal disease risks through metabolic-immune interplay in the gut-liver axis: insights from a multi-omics study
{{output}}
Aims: Glucokinase activators (GKAs) lower glucose by directly activating glucokinase (GK) or dissociating it from GK regulatory protein (GK-GKRP). Their long-term effects on gastrointestinal (GI) diseases remain unclear. This stu... ...
